Petros Pharmaceuticals, Inc. (PTPI)
OTCMKTS · Delayed Price · Currency is USD
0.0215
+0.0013 (6.49%)
At close: Oct 28, 2025
Petros Pharmaceuticals Revenue
Petros Pharmaceuticals had revenue of $5.11M in the twelve months ending June 30, 2025, up 290.11% year-over-year. In the year 2024, Petros Pharmaceuticals had annual revenue of $5.11M, down -12.20%.
Revenue
5.11M
Revenue Growth
+290.11%
P/S Ratio
0.18
Revenue / Employee
284.00K
Employees
18
Market Cap
911.00K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.11M | -710.35K | -12.20% |
| Dec 31, 2023 | 5.82M | -169.67K | -2.83% |
| Dec 31, 2022 | 5.99M | -1.82M | -23.29% |
| Dec 31, 2021 | 7.81M | -1.75M | -18.29% |
| Dec 31, 2020 | 9.56M | -6.02M | -38.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Petros Pharmaceuticals News
- 4 months ago - Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position - Accesswire
- 5 months ago - Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets - Accesswire
- 5 months ago - Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development - Seeking Alpha
- 5 months ago - Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer - Accesswire
- 6 months ago - Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform - Accesswire
- 6 months ago - Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches - Accesswire
- 6 months ago - Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms - Accesswire
- 7 months ago - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications - Accesswire